Attention Deficit Disorder With Hyperactivity Clinical Trial
Official title:
Cortical Correlates of Subtle Motor Signs in Attention-Deficit/Hyperactivity Disorder and Healthy Controls
Attention deficit/hyperactivity disorder is a condition characterized by a decreased
attention span, hyperactivity, and/or impulsiveness inappropriate for a certain age.
Typically, young children have what are known as subtle neurological signs. These are
involuntary movements of one part of the body that occur while the child is making a
voluntary movement of another part of the body. This is referred to as synkinesis, or
overflow movements. These overflow movements disappear during normal development and are
usually gone by the age of 10. However, in children with ADHD these overflow movements tend
to be more intense and last long after the age of 10. This leads researchers to believe
there is an abnormality in the maturation and development of the brain areas associated with
motor activity in children with ADHD.
Transcranial Magnetic Stimulation (TMS) is a non-invasive technique that gives information
about brain function. It is very useful when studying areas of the nervous system related to
motor activity (motor cortex, corticospinal tract, and corpus callosum). A magnetic signal
given from a special instrument held close to the patient's head stimulates a small area of
the brain that controls a few muscles (for example, the muscles that control one finger).
Doctors put electrodes (small pieces of metal taped to areas of the body) over the muscle to
measure the electrical activity the muscle produces when it makes a movement. When the
magnetic signal activates those muscles the electrodes pick up and record the electrical
activity of the movement that the muscles make in response to the magnetic signal.
Researchers will study normal children and those diagnosed with ADHD using TMS to find out
if the clinical abnormalities of ADHD are associated with a delay or abnormality in
maturation of areas of the nervous system responsible for motor activity (motor cortex and
corticospinal tract).
| Status | Completed |
| Enrollment | 200 |
| Est. completion date | February 2004 |
| Est. primary completion date | |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Both |
| Age group | N/A and older |
| Eligibility |
INCLUSION CRITERIA: Boys and girls 9 to 13 years of age. Right handed subjects only. Subjects that are off stimulant medications. Children who undergo a medication washout as a part of a different study or are on a planned drug holigay will be allowed to enroll in the study once they have bee off the medications for at least 10 days. Adult men with a history of ADHD between 18 and 30 years and healthy age-matched normal volunteers. EXCLUSION CRITERIA: Patients with neurological disorders will be excluded. In particular, persons with a personal or family history of seizures or epilepsy; structural cerebral disorders (e.g. hemiplegia or other abnormalities of the corticospinal tracts). We will also exclude from our study any persons who have a personal or family history of sensorineural loss. Person with abnormally decreased pigmentation (albinism) will also be excluded from the study. Patients with a chronic motor or vocal tic disorder or Tourette Syndrome. Children with tics, not meeting DSM-III criteria for tic disorder will be allowed to enroll in the study. Children with localizing neurological signs (asymmetric deep tendon reflexes (DTRs), dysmetria, hypotonia) will also be excluded. Children with psychiatric disorders other than oppositional defiant disorder (ODD) will be excluded from study. Children who have dyslexia and learning disabilities but do not have ADHD will be excluded. Children with ADHS who are on a stimulant medication will be excluded from enrollment in the study. HEALTHY CONTROLS: Healthy controls cannot have any of the exclusionary conditions mentioned above and, by definition, must necessarily be free of ADHD symptoms. |
N/A
| Country | Name | City | State |
|---|---|---|---|
| United States | National Institute of Neurological Disorders and Stroke (NINDS) | Bethesda | Maryland |
| Lead Sponsor | Collaborator |
|---|---|
| National Institute of Neurological Disorders and Stroke (NINDS) |
United States,
Connolly K, Brown K, Bassett EE. Developmental changes in some components of a motor skill. Br J Psychol. 1968 Aug;59(3):305-14. — View Citation
Denckla MB. Development of motor co-ordination in normal children. Dev Med Child Neurol. 1974 Dec;16(6):729-41. — View Citation
Denckla MB. Development of speed in repetitive and successive finger-movements in normal children. Dev Med Child Neurol. 1973 Oct;15(5):635-45. — View Citation
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00202605 -
Safety and Efficacy of SPD465 in Adults With ADHD
|
Phase 2 | |
| Not yet recruiting |
NCT02677519 -
A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD
|
Phase 4 | |
| Completed |
NCT02730572 -
Concerta (Methylphenidate) -To-Generic Switch Study
|
N/A | |
| Completed |
NCT01681082 -
Psychological Effects of Tai Chi Training
|
N/A | |
| Active, not recruiting |
NCT01330693 -
Cortical Excitability: Phenotype and Biomarker in Attention-deficit, Hyperactivity Disorder (ADHD) Therapy
|
Phase 3 | |
| Completed |
NCT00830700 -
Children's Attention Deficit Disorder With Hyperactivity (ADHD) Telemental Health Treatment Study
|
N/A | |
| Completed |
NCT01012622 -
An Efficacy and Safety Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention Deficit Hyperactivity Disorder (ADHD)
|
Phase 4 | |
| Completed |
NCT00626236 -
Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct Problems
|
Phase 2 | |
| Completed |
NCT00598182 -
Adherence and Long-term Effect of OROS Methylphenidate (CONCERTA): A Follow-up Study
|
N/A | |
| Completed |
NCT00381407 -
Organizational Skills Training for Children With Attention Deficit Hyperactivity Disorder
|
N/A | |
| Completed |
NCT00178503 -
Methylphenidate for Attention Deficit Hyperactivity Disorder and Autism in Children
|
Phase 2/Phase 3 | |
| Completed |
NCT00247572 -
Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories
|
Phase 2 | |
| Completed |
NCT00557011 -
NRP104, Adderall XR or Placebo in Children Aged 6-12 Years With ADHD
|
Phase 2 | |
| Completed |
NCT00118911 -
Cognitive Behavioral Therapy for Treatment of Adult Attention Deficit Hyperactivity Disorder
|
N/A | |
| Completed |
NCT00218322 -
Effectiveness of ATMX in Treating Adolescents With ADHD and SUD
|
Phase 4 | |
| Completed |
NCT00071656 -
Psychosocial Treatment for Attention Deficit Hyperactivity Disorder (ADHD) Type I
|
N/A | |
| Active, not recruiting |
NCT00057668 -
Preventing Behavior Problems in Children With ADHD
|
Phase 2 | |
| Completed |
NCT00050050 -
Cognitive Behavioral Therapy for Adult Attention Deficit Hyperactivity Disorder
|
Phase 1 | |
| Completed |
NCT00050622 -
Behavioral Treatment, Drug Treatment, and Combined Treatment for Attention Deficit Hyperactivity Disorder (ADHD)
|
N/A | |
| Completed |
NCT00031395 -
Clonidine in Attention Deficit Hyperactivity Disorder (ADHD) in Children
|
Phase 3 |